BellBrook Labs, LLC

BellBrook Labs, LLC is an R&D-driven biotechnology company that develops enabling high-throughput screening (HTS) assay platforms to accelerate enzyme-targeted drug discovery. The company is primarily known for its proprietary Transcreener® HTS technology, which utilizes homogeneous fluorescent immunodetection of nucleotides—such as ADP, UDP, and GDP—to measure enzymatic activity. This platform allows researchers to perform inhibitor screening and profiling across thousands of diverse enzyme families, including kinases, ATPases, GTPases, and methyltransferases. By providing a generic, robust method for detecting enzyme-catalyzed reactions, the technology streamlines the assay development process and helps researchers move new therapeutic targets into high-throughput screening more rapidly. In recent years, the company has expanded its portfolio to include Enzolution™ HTS enzyme assays, which provide complete, ready-to-use solutions featuring validated enzymes and optimized protocols.

The company's products and services are utilized by pharmaceutical, biotechnology, and academic researchers worldwide to develop therapeutics for conditions such as cancer, metabolic diseases, cardiovascular disorders, and autoimmune conditions. BellBrook Labs partners with organizations to offer customized drug discovery services, including biochemical assay development and lead discovery support, often helping partners navigate complex technical hurdles in early-stage research. By delivering validated, high-quality data and tools, BellBrook Labs aims to provide speed and scientific rigor to drug discovery workflows, enabling clients to make informed go/no-go decisions. Their solutions have been used to screen tens of millions of wells in drug discovery programs, assisting scientists in the critical effort to identify and optimize effective disease-modulating drug molecules.